Gilead Sciences Reports Promising CAR-T Therapy Results for Glioblastoma Treatment

Gilead Sciences has reported promising results for its CAR-T cell therapy in the treatment of glioblastoma, a highly aggressive and deadly form of brain cancer. The findings suggest potential advancements in addressing this challenging disease, which currently has limited effective treatment options. The announcement highlights progress in the use of CAR-T technology, a method that modifies patients’ immune cells to target and destroy cancer cells.

In other developments within the pharmaceutical industry, Sanofi has expanded its rare immunology portfolio through the acquisition of Blueprint Medicines. Moderna received FDA backing for its next-generation COVID-19 vaccine, though with certain limitations on its use. Meanwhile, BioNTech announced it had sold its bispecific cancer antibody program to Bristol Myers Squibb (BMS), generating significant profit from the transaction. These updates reflect ongoing innovation and strategic moves across major players in the healthcare sector as they continue to address critical medical needs globally.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 2, 2025

Related posts:

AI-Driven Generic Drug Development: Automation Improves Quality Control, Particle Size Analysis, and Opens Door to Personalized Medicine Pharmaceutical Companies Extend Drug Patents Using Method-of-Use Strategies Post-ANDA. Bavarian Nordic First Quarter Revenue Exceeds 2024 Amidst Evolving Vaccine Market Mandatory Human Abuse Liability Assessment Gains Role in Drug Scheduling and Regulatory Compliance

Author

Mark Chiang